Pembrolizumab seems to be a new immune checkpoint inhibitor option for NSCLC, however is our knowledge on tumour biomarkers enough?

Lung cancer is one of the leading causes of cancer-related deaths around the world. Despite the development of third-generation drugs combined with platinum compounds and different maintenance therapies, the overall survival achieved by cytotoxic agents was no longer than 15 months. 

Pembrolizumab has shown a manageable toxicity profile with less than 10% of grade 3 or 4 adverse events and pneumonitis incidence of less than 4% with a severity of grade 3 to 5 in half the patients.

The most important question is: this treatment is indicated for whom?

Read more here.